[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Prelude Therapeutics Inc (PRLD)

Prelude Therapeutics Inc (PRLD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 460,348
  • Shares Outstanding, K 79,645
  • Annual Sales, $ 12,140 K
  • Annual Income, $ -99,500 K
  • EBIT $ -67 M
  • EBITDA $ -66 M
  • 60-Month Beta 0.96
  • Price/Sales 37.72
  • Price/Cash Flow N/A
  • Price/Book 3.35

Options Overview Details

View History
  • Implied Volatility 145.59% (-1.14%)
  • Historical Volatility 85.89%
  • IV Percentile 9%
  • IV Rank 3.70%
  • IV High 865.09% on 09/25/25
  • IV Low 117.93% on 07/06/26
  • Expected Move (DTE 1) 0.51 (8.82%)
  • Put/Call Vol Ratio 0.06
  • Today's Volume 176
  • Volume Avg (30-Day) 162
  • Put/Call OI Ratio 0.51
  • Today's Open Interest 5,065
  • Open Int (30-Day) 4,750
  • Expected Range 5.27 to 6.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.16
  • Number of Estimates 1
  • High Estimate $-0.16
  • Low Estimate $-0.16
  • Prior Year $-0.26
  • Growth Rate Est. (year over year) +38.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.77 +53.32%
on 07/24/26
5.91 -2.20%
on 08/13/26
+1.58 (+37.62%)
since 07/17/26
3-Month
3.40 +70.00%
on 06/03/26
5.91 -2.20%
on 08/13/26
+1.51 (+35.36%)
since 05/19/26
52-Week
0.85 +578.01%
on 08/20/25
5.91 -2.20%
on 08/13/26
+4.89 (+547.11%)
since 08/19/25

Most Recent Stories

More News
Can Prelude Therapeutics Finally Deliver a Quarter Without Expanding Its Cash Burn?

Barchart Research What to Expect from PRLD Earnings PRLD Generated August 12, 2026 Current Price $5.73 EPS Estimate $$-0.16 Consensus Rating Strong Buy Average Move 7.07% Can Prelude Therapeutics Finally...

PRLD : 5.78 (+0.52%)
Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

The Company expects to initiate its Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer in the fourth quarter Presented preclinical data demonstrating...

PRLD : 5.78 (+0.52%)
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF) The Company expects to file the IND for PRT13722,...

PRLD : 5.78 (+0.52%)
Prelude Therapeutics Reports While Its Option Clock Keeps Ticking

Barchart Research What to Expect from PRLD Earnings PRLD Generated May 11, 2026 Current Price $4.80 EPS Estimate $$-0.27 Consensus Rating Strong Buy Average Move 7.39% Prelude Therapeutics Reports While...

PRLD : 5.78 (+0.52%)
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering

WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced...

PRLD : 5.78 (+0.52%)
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026

Data Demonstrate Potential for Differentiated Efficacy and Safety Profile, Including Complete Responses as Monotherapy in Multiple CDX and PDX Models of HR+/HER2- Breast Cancer  Prelude Remains on...

PRLD : 5.78 (+0.52%)
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer

WILMINGTON, Del., April 15, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude Therapeutics” or the “Company”), a clinical-stage precision oncology company, today...

PRLD : 5.78 (+0.52%)
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting

WILMINGTON, Del., March 17, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that a poster with preclinical data on the Company’s...

PRLD : 5.78 (+0.52%)
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026

Received FDA clearance of Investigational New Drug application (IND) for PRT12396, mutant-selective JAK2V617F inhibitor in the first quarter of 2026 Phase 1 study of PRT12396 in patients with polycythemia...

PRLD : 5.78 (+0.52%)
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor

WILMINGTON, Del., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) cleared...

PRLD : 5.78 (+0.52%)

Business Summary

Prelude Therapeutics Incorporated is a clinical-stage precision oncology company. It is focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. Prelude Therapeutics Incorporated is based in Wilmington, United States....

See More

Key Turning Points

3rd Resistance Point 6.14
2nd Resistance Point 6.02
1st Resistance Point 5.90
Last Price 5.78
1st Support Level 5.66
2nd Support Level 5.54
3rd Support Level 5.42

See More

52-Week High 5.91
Last Price 5.78
Fibonacci 61.8% 3.98
Fibonacci 50% 3.38
Fibonacci 38.2% 2.78
52-Week Low 0.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.